Brighthaven Ventures' Merger

Brighthaven Ventures raised a round of funding on October 01, 2014. Investors include Islet Sciences.

Brighthaven Ventures, dba BHV Pharma, is developing a novel, best in class, Sodium Glucose Transporter 2 (SGLT2) inhibitor indicated for Type 2 Diabetes and NASH. Remogliflozin has been dosed in over …

Articles about Brighthaven Ventures' Merger: